目的:探讨参附注射液与依达拉奉注射液联合治疗急性脑梗死的临床疗效.方法:选取2014年6月—2016年6月衡阳市中医医院收治的急性脑梗死患者120例,以随机数字表法分为对照组和观察组,每组60例.对照组患者给予依达拉奉注射液,观察组患者在对照组基础上联合应用参附注射液,均治疗14 d.比较两组患者治疗前后的日常生活活动能力(activities of daily living,ADL)、美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分、炎性因子水平、临床疗效和不良反应发生情况.结果:治疗前,两组患者ADL、NIHSS评分,C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)水平的差异均无统计学意义(P>0.05).治疗后,两组患者的ADL评分均显著升高,且观察组患者明显高于对照组;两组患者的NIHSS评分,CRP、TNF-α和IL-6水平均明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05).观察组患者的总有效率为93.33%(56/60),明显高于对照组的80.00%(48/60),差异有统计学意义(P<0.05).观察组患者不良反应发生率为6.67%(4/60),对照组为3.33%(2/60),两组的差异无统计学意义(P>0.05).结论:参附注射液与依达拉奉注射液联合治疗急性脑梗死,疗效显著,安全性高.
OBJECTIVE:To probe into the clinical efficacy of Shenfu injection combined with edaravone injection in treatment of acute cerebral infarction .METHODS:120 patients with acute cerebral infarction admitted into Hengyang Traditional Chinese Medicine Hospital from Jun .2014 to Jun.2016 were selected and divided into control group and observation group via random number table , with 60 cases in each group .The control group was treated with edaravone injection, while the observation group was given Shenfu injection combined with edaravone injection , both groups received a 14-day treatment.The activities of daily living(ADL), national institutes of health stroke scale(NIHSS) scores and levels of inflammatory factors between two groups before and after treatment were compared , the clinical efficacy and incidence of adverse drug reactions of two groups were observed .RESULTS:Before treatment , there was no statistical significance in levels of ADL scores, NIHSS scores, C-reactive protein(CRP), tumor necrosis factor α(TNF-α) and interleukin 6(IL-6) between two groups(P>0.05).After treatment, the ADL scores of both groups had been significantly increased , and that of the observation group was significantly higher than the control group;the NIHSS scores , CRP, TNF-αand IL-6 of both groups had been significantly decreased , and those of the observation group were significantly lower than the control group , with statistically significant differences (P<0.05).The total effective rate of observation group was 93.33%(56/60), which was significantly higher than that of the control group (80.00%, 48/60), with statistically significant difference(P<0.05). The incidence of adverse drug reactions of observation group was 6.67%(4/60) , that of the control group was 3.33%(2/60), the difference had no statistical significance (P>0.05).CONCLUSIONS:The efficacy of Shenfu injection combined with edaravone injection in treatment of acute cerebral infarction is remarkable , with high safety.